Ajman University

Community pharmacies in low- and middle-income countries (LMICs) are widely accessible yet underutilized due to regulatory constraints, educational disparities, public misconceptions, and economic pressures. These factors limit pharmacists' roles to mere dispensers, hindering their integration into healthcare systems. Addressing this paradox requires regulatory reforms, alignment of education with practice, public awareness campaigns, and systemic integration to fully leverage community pharmacies' potential in enhancing healthcare delivery.

Chronic Kidney Disease (CKD) represents a significant worldwide health challenge, with far-reaching implications for both patients and healthcare systems. This study aimed to identify the incidence of CKD at stages 3-5, analyzed the impact of statin and other antihyperglycemic interventions, on the CKD progression in individuals with T2DM.

This was a single-center retrospective cohort study based on data derived from electronic medical records (EMR) of UAE populations with diabetes mellitus, registered at outpatient clinics at Tawam Hospital in Al Ain, UAE, between January 2011 and December 2021. T2DM patients aged ≥ 18 years who had serum HbA1c level ≥ 6.5% and using one of the statin therapies were inclusion criteria. Patients with T1DM, who had undergone permanent renal replacement therapy, with under 1 year of follow-up and missing or incomplete data were excluded from the study. The collected data encompassed socio-demographics, detailed medical history, anthropometric measurements, laboratory analyses, clinical parameters, disease characteristics, and medications.

Our study included a cohort of 1,003 individuals. We observed 388 subjects developed CKD stages 3-5 across an average monitoring duration of 11.7 years. This resulted in a cumulative incidence of 38.7%, translating to an incidence rate of 38 cases per 1000 person-years. There was a statistically significant difference in the cumulative incidence of CKD stages 3 ± 5 according to statin therapy (P = 0.047). High intensity statin users are more likely to develop a CKD stage 3-5 compared to low/moderate intensity users and to no statin users respectively (44.3% vs 37.9%), (44.3% vs 30.9%). Conversely, the use of Biguanides was associated with a decreased probability of CKD progression (37.9% vs. 52.8%; P = 0.001), whereas Insulin users demonstrated a heightened risk (54.2% vs. 34.1%; P < 0.001).

The findings emphasise the pivotal role of personalised treatment strategies, particularly concerning statin therapy and other medications, in populations at high risk.

Colour-coded zones for rapidly dispensed medications are a simple, yet game-changing solution to improve the efficiency and safety of hospital pharmacy systems. This approach integrates visual ergonomics, staff training, and technology in solving some of the most common challenges in medication retrieval and general healthcare delivery. This evidence-based system will go a long way in helping hospitals meet the ever-increasing demands. While colour-coded zoning schemes offer a practical and cost-effective way to enhance pharmacy efficiency and medication safety, their effectiveness depends on careful implementation, standardisation, and integration with digital tools. Although highly digitalised healthcare systems may rely more on automated inventory tracking and barcode verification, colour coding remains a valuable supplementary measure, particularly in fast-paced clinical environments. For resource-limited healthcare facilities, colour-coded zoning serves as an essential safety mechanism where advanced IT solutions may not be feasible. However, standardisation challenges, risks of over-reliance, and accessibility concerns for colour-blind individuals must be addressed to maximise effectiveness. Ultimately, an optimal pharmacy management system may involve a hybrid approach that integrates both visual and digital verification methods, ensuring both efficiency and patient safety across diverse healthcare settings.